90 results on '"Pfizer Inc. -- Product development -- Forecasts and trends"'
Search Results
2. Atopic Dermatitis Treatment Market 2034: Clinical Trials, EMA, PDMA, FDA Approvals, Medication, Patient Pool, and Companies DelveInsight
3. PD-1 Non-Small Cell Lung Cancer Treatment Market 2034: EMA, PDMA, FDA Approvals, Medication, Prevalence, Therapies, Clinical Trials and Companies by DelveInsight
4. Obsessive Compulsive Disorder Treatment Market 2034: Clinical Trials, EMA, PDMA, FDA Approvals, Medication, Revenue, Statistics, Therapies, Prevalence, Companies by DelveInsight
5. Urothelial Carcinoma Treatment Market 2034: Clinical Trials, EMA, PDMA, FDA Approvals, Medication, Revenue, Statistics, Therapies, Prevalence, Companies by DelveInsight
6. Respiratory Syncytial Virus Treatment Market 2034: Clinical Trials, EMA, PDMA, FDA Approvals, Medication, Revenue, Statistics, Therapies, Prevalence, Companies by DelveInsight
7. Hemophilia B Treatment Market 2034: EMA, PDMA, FDA Approvals, Clinical Trials, Medication, Pipeline, Epidemiology and Companies by DelveInsight
8. Head and Neck Squamous Cell Carcinoma Treatment Market 2032: EMA, PDMA, FDA Approvals, Clinical Trials, Pipeline, Epidemiology and Companies by DelveInsight
9. Chemotherapy Induced Anemia Treatment Market 2032: Clinical Trials, Medication, Prevalence, Incidence, Therapies, EMA, PDMA, FDA Approvals, and Companies by DelveInsight
10. Non-Muscle Invasive Bladder Cancer Treatment Market 2034: Clinical Trials, Medication, Prevalence, Incidence, Therapies, EMA, PDMA, FDA Approvals, and Companies by DelveInsight
11. Corneal Ulcer Treatment Market 2034: Clinical Trials, Medication, Prevalence, Incidence, Therapies, EMA, PDMA, FDA Approvals, and Companies by DelveInsight
12. Candidemia Treatment Market 2034: Clinical Trials, Medication, Prevalence, Incidence, Therapies, EMA, PDMA, FDA Approvals, and Companies by DelveInsight
13. Psychosis in Parkinson's Disease and Alzheimer's Disease Treatment Market 2034: Clinical Trials, EMA, PDMA, FDA Approvals, Epidemiology, Therapies, Companies by DelveInsight
14. Menopause Treatment Market 2034: Clinical Trials, EMA, PDMA, FDA Approvals, Epidemiology, Therapies, Companies by DelveInsight | Bayer, GSK, Pfizer, Centro A.F. de Estudios Tecnologicos, S.A., more
15. Acoustic Neuroma Treatment Market 2032: FDA Approval, Clinical Trials, Prevalence, Therapies and Companies by DelveInsight
16. Cancer Cachexia Market Report 2034: FDA, EMA, PDMA Approvals, Clinical Trials, Pipeline, Epidemiology, and Companies by DelveInsight
17. Janus Kinase Inhibitors Competitive Landscape Insights | Clinical Trials, Latest Approvals, Therapies, Key Companies | Pfizer, Sierra Oncology, Theravance Biopharma, Dizal Pharmaceutical, Aclaris
18. Post-Bariatric Hypoglycemia Market Forecast 2032: FDA, EMA, PDMA Approvals, Clinical Trials, Therapies, Epidemiology and Companies by DelveInsight | Pasireotide Diaspartate, glucagon, Lyo avexitide
19. Chemotherapy Induced Anemia Market Forecast 2032: FDA, EMA, PDMA Approvals, Clinical Trials, Drugs, Epidemiology and Companies by DelveInsight | Roxadustat (FG-4592), ALRN-6924, Desidustat
20. Bladder Cancer Market Forecast 2032: FDA, EMA, PDMA Approvals, Clinical Trials, Epidemiology, Therapies and Companies by DelveInsight
21. Ulcerative Colitis Market Analysis 2032: Epidemiology, Market Size, Drugs, FDA Approval, Clinical Trials, Companies and Competitive Landscape by DelveInsight
22. Diabetic Neuropathic Pain Market and Epidemiology 2032: Clinical Trials, Therapies, FDA Approvals, Companies and Patient based Forecast by DelveInsight
23. Rheumatoid Arthritis Market Analysis 2032: Epidemiology, Market Size and Share, FDA Approval, Clinical Trials and Companies by DelveInsight
24. Opinion: 2024 Will Be A Buyers' Market In Biopharma. It Already Is
25. Systemic Sclerosis Pipeline Assessment Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals | Certa Therapeutics, Eicos, Sanofi, Bayer, Janssen, Gesynta,, Pfizer, Seagen, CSL
26. Abscess Treatment Market 2032: Epidemiology, Clinical Trials, Therapies, FDA Approvals and Companies by DelveInsight | Mission Pharmacal, Durata Therapeutics Co, Debiopharma Group, UCB Pharma, Pfizer
27. Chronic Plaque Psoriasis Market, Epidemiology, Clinical Trials and FDA Approvals by DelveInsight | Arcutis, Dermavant Sciences, UCB, BMS, Merck, Pfizer, Boehringer
28. The Herpes Zoster Market is expected to strengthen as awareness of the disease increases and more effective interventions are being developed
29. Propulsion of Small Lymphocytic Lymphoma Clinical Trial Pipeline as Novel and Extensive 80+ Therapies Likely to Enter in the Domain | DelveInsight
30. Myositis Clinical Trial Pipeline Analysis Demonstrates 20+ Key Companies at the Horizon Expected to Transform the Treatment Paradigm, Assesses DelveInsight
31. Respiratory Syncytial Virus (RSV) Pipeline Analysis (2023) Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals, Competitive Landscape | Enanta, ReViral, Pfizer, Sanofi, BioComo
32. Advanced Endometrial Cancer Pipeline Analysis (2023) Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals, Competitive Landscape | Incyte, Byondis, Genentech, Zymeworks, Pfizer
33. B-Cell Lymphomas Pipeline Analysis (2023) Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals, Competitive Landscape | Oncternal, ZAI Lab, Pfizer, SystImmune, Vincerx, InnoCare
34. Psoriatic Arthritis Pipeline Analysis (2023) Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals, Competitive Landscape | Mylan, Celltrion, Pfizer, Amgen, CinnaGen, Biogen, UC
35. Prostate Cancer Pipeline Analysis Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals, Competitive Landscape | Astellas, Pfizer, Janssen, Roche, Merck, Bayer, Advantagene
36. Esophageal Cancer Pipeline Analysis (2023) Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals, Competitive Landscape | BeiGene, Amgen, Oncolys, Pfizer, Novartis, TESARO
37. Bladder Cancer Pipeline Analysis (2023) Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals, Competitive Landscape | RemeGen, UroGen, Asieris, Pfizer, Roche, Protara, Emtora
38. Glioma Pipeline Analysis (2023) Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals, Competitive Landscape | Denovo, Pfizer, Chimerix, AiVita, Ascletis, Immunomic, Roche, Vigeo
39. Hypersomnia Pipeline Analysis (2023) Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals, Competitive Landscape | Takeda, KemPharm, Orexia, Pfizer, Eisai, Axsome Therapeutics
40. ER+/ HER2 -ve Breast Cancer Pipeline Analysis Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals, Competitive Landscape | BeiGene, Novartis, Pfizer, AstraZeneca, Roche, EQRx
41. Post-Traumatic Stress Disorder (PTSD) Pipeline Analysis (2023) Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals, Competitive Landscape | Aptinyx, Nobilis, Pfizer, Bionomics
42. Cancer Cachexia Pipeline Analysis Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals, Competitive Landscape | AEterna Zentaris, Pfizer, Incyte, Smartfish, Caelus, Helsinn
43. Ulcerative Colitis Pipeline Analysis (2023) Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals, Competitive Landscape | Eli Lilly, AbbVie, Pfizer, Arena Pharma, Janssen
44. PARP Inhibitors Clinical Trial Pipeline: DelveInsight Highlights Major Advances, Transformative Therapies, and 20+ Leading Players Wheeling the Therapeutics Landscape
45. Advanced Renal Cell Carcinoma Clinical Trial Pipeline Space Brims With Novel Emerging Therapies with Over 50 Key Companies Working in the Domain | DelveInsight
46. Adeno-Associated Virus Vector-Based Gene Therapies Market Report 2032: Epidemiology, Market Size, Share, Therapies, Clinical Trials, Companies & Growth Analysis Report by DelveInsight
47. Metastatic Castration-Resistant Prostate Cancer (mCRPC) Pipeline Assessment (2023) Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals | Regeneron, Pfizer, Progenics, Bayer
48. Smoking Cessation Pipeline Assessment (2023) Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals | CTC Bio, Eolas, GlaxoSmithKline, NFL Biosciences, Novo Nordisk, Pfizer
49. Global Pneumococcal Vaccines (PV) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
50. Sickle Cell Disease Clinical Trial Pipeline Accelerates as 40+ Pharma Companies Rigorously Developing Drugs for the Market Entry
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.